<div>
  <ul>
    <li>
      <p>
        AI-driven drug development company Insilico Medicine and invoX Pharma, a research-driven global biopharmaceutical company, have teamed up to improve R&amp;D in oncology with the help of AI, computational services, and data science. The terms and financial details of the partnership have not been disclosed.
      </p>
    </li>
    <li>
      <p>
        The partnership will leverage Insilico&rsquo;s proprietary AI platform, PandaOmics, with invoX&rsquo;s drug discovery, development, and data science capabilities to identify potential uses for drugs in development within invoX&rsquo;s current pipeline. This collaboration also plans to train large AI models to be used in multiple projects, initiating new uses throughout the term of the partnership.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://invoxpharma.com/news/investment/invox-pharma-and-insilico-medicine-enter-into-collaboration-to-enhance-research-and-development-using-artificial-intelligence/">
      Press release
    </a>
  </p>
</div>


AI Drug Discovery

PROMINENT_CATEGORY

<div>
 <p>Insilico Medicine, an AI-based drug development company, and invoX Pharma, a global biopharmaceutical company, have formed a partnership to enhance research and development in oncology by using AI, computational services, and data science. The specifics and financial aspects of the partnership have not been revealed.</p>
 <p>Through the partnership, they intend to combine Insilico’s proprietary AI platform, PandaOmics, with invoX's drug discovery, development, and data science expertise to determine potential applications for drugs currently in development within invoX’s pipeline. The partnership also aims to train substantial AI models for deployment in multiple projects, thus fostering new uses across the duration of the partnership.</p>
 
</div>

Insilico Medicine and invoX Pharma collaborate to enhance oncology research and development through AI

<div>
 
 <p>Hong Kong-based AI drug discovery company Insilico Medicine has started Phase I clinical trials for its fifth AI-discovered drug ISM5411. The drug is aimed at treating inflammatory bowel disease (IBD), a gastrointestinal disease.</p>
 <p>ISM5411 is an oral drug designed by Insilico's AI platform, Pharma.AI. It is a prolyl hydroxylase domain enzyme (PHD) inhibitor that protects the gut barrier by promoting the expression of genes.</p>
 <p>The Phase I study has begun in Australia with healthy volunteers, and the company plans to expand to a global multi-center Phase Ib trial involving patients with ulcerative colitis.</p>
 
</div>

Insilico Medicine initiates Phase I study for IBD drug

Longevity Tech

DISRUPTOR_PRESENT

<div>
 
 <ul>
  <li><p>Drug discovery and repurposing company Insilico Medicine is partnering with SRW Laboratories to develop longevity products to extend health span.</p></li>
  <li><p>Using AI and Insilico's Pharma.AI platform, the alliance will identify natural compounds that promote healthy aging, develop new therapeutics, and forecast clinical trial results. The partnership has already started, and the first product suite is anticipated to launch in 2024.</p></li>
 </ul>
 
</div>

Insilico Medicine partners with SRW Laboratories to develop AI-powered longevity nutraceuticals

Insilico Medicine, an AI drug discovery company based in Hong Kong, has signed an exclusive license agreement with pharmaceutical company Exelixis for the development and commercialization of an AI-generated cancer treatment called ISM3091. Exelixis will pay an upfront fee of $80 million to Insilico in 2023 and will also make future payments and royalties based on the success of ISM3091. The partnership will give Exelixis global rights to ISM3091, a small molecule that targets USP1 and provides a unique treatment option for BRCA-mutated tumors. The collaboration also aims to accelerate the enrollment of ISM3091 in Phase I trials.

All Updates

Insilico Medicine and invoX Pharma collaborate to enhance oncology research and development through AI

Insilico Medicine initiates Phase I study for IBD drug

Insilico Medicine partners with SRW Laboratories to develop AI-powered longevity nutraceuticals

Insilico Medicine enters license collaboration with Exelixis for AI-generated cancer diagnosis

Insilico begins industry-first Phase II trial of AI-discovered drug; files for IPO in Hong Kong

Insilico Medicine and Sanofi sign a USD 1.2 billion AI deal

Insilico Medicine raises USD 60 million in Series D

Insilico Medicine collaborates with EQRx for multi-target drug discovery

Insilico Medicine and University of Zurich enter into R&D collaboration

Insilico Medicine and Fosun Pharma team up for multi-target AI drug development

All Updates

Insilico Medicine and invoX Pharma collaborate to enhance oncology research and development through AI

Insilico Medicine initiates Phase I study for IBD drug

Insilico Medicine partners with SRW Laboratories to develop AI-powered longevity nutraceuticals

Insilico Medicine enters license collaboration with Exelixis for AI-generated cancer diagnosis

Insilico begins industry-first Phase II trial of AI-discovered drug; files for IPO in Hong Kong

​​Insilico Medicine and Sanofi sign a USD 1.2 billion AI deal

Insilico Medicine raises USD 60 million in Series D

Insilico Medicine collaborates with EQRx for multi-target drug discovery

Insilico Medicine and University of Zurich enter into R&D collaboration

Insilico Medicine and Fosun Pharma team up for multi-target AI drug development

Insilico Medicine and Sanofi sign a USD 1.2 billion AI deal